stratascript rnase h-reverse transcriptase (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
stratascript rnase h-reverse transcriptase
Stratascript Rnase H Reverse Transcriptase, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stratascript+rnase+h-reverse+transcriptase/10__1016_slash_S0028___3908_ascii40_00_ascii41_00144___1-66-26-30
Average 90 stars, based on 1 article reviews
Stratascript Rnase H Reverse Transcriptase, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stratascript+rnase+h-reverse+transcriptase/10__1016_slash_S0028___3908_ascii40_00_ascii41_00144___1-66-26-30
Average 90 stars, based on 1 article reviews
stratascript rnase h-reverse transcriptase - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Polymerase Chain Reaction:Article Title: Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses Article Snippet: Many nicotinic acetylcholine receptor (AChR) subunits are known to be co-expressed with the α6 subunit in neurons.. Because α6β4 AChRs assemble inefficiently and α6β2 AChRs not at all, more complex mixtures of human subunit cDNAs were tested for their abilities to form functional AChRs when expressed in Xenopus oocytes. α6β4β3 AChRs produced the largest and most consistent responses. α6α3β2 AChRs exhibited reduced potency for ACh and increased potency and efficacy for nicotine compared to α3β2 AChRs, but similar resistance to functional inactivation after prolonged exposure to nicotine. α6α4β2 AChRs differed little in potency or efficacy for ACh or nicotine compared to α4β2 AChRs, and had similarly high sensitivity to inactivation by prolonged exposure to nicotine.. Co-expression of α6 and β2 cRNAs resulted in large numbers of H-epibatidine binding sites in the form of large aggregates but not in functional pentameric AChRs. Amplification:Article Title: Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses Article Snippet: Many nicotinic acetylcholine receptor (AChR) subunits are known to be co-expressed with the α6 subunit in neurons.. Because α6β4 AChRs assemble inefficiently and α6β2 AChRs not at all, more complex mixtures of human subunit cDNAs were tested for their abilities to form functional AChRs when expressed in Xenopus oocytes. α6β4β3 AChRs produced the largest and most consistent responses. α6α3β2 AChRs exhibited reduced potency for ACh and increased potency and efficacy for nicotine compared to α3β2 AChRs, but similar resistance to functional inactivation after prolonged exposure to nicotine. α6α4β2 AChRs differed little in potency or efficacy for ACh or nicotine compared to α4β2 AChRs, and had similarly high sensitivity to inactivation by prolonged exposure to nicotine.. Co-expression of α6 and β2 cRNAs resulted in large numbers of H-epibatidine binding sites in the form of large aggregates but not in functional pentameric AChRs. Synthesized:Article Title: Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses Article Snippet: Many nicotinic acetylcholine receptor (AChR) subunits are known to be co-expressed with the α6 subunit in neurons.. Because α6β4 AChRs assemble inefficiently and α6β2 AChRs not at all, more complex mixtures of human subunit cDNAs were tested for their abilities to form functional AChRs when expressed in Xenopus oocytes. α6β4β3 AChRs produced the largest and most consistent responses. α6α3β2 AChRs exhibited reduced potency for ACh and increased potency and efficacy for nicotine compared to α3β2 AChRs, but similar resistance to functional inactivation after prolonged exposure to nicotine. α6α4β2 AChRs differed little in potency or efficacy for ACh or nicotine compared to α4β2 AChRs, and had similarly high sensitivity to inactivation by prolonged exposure to nicotine.. Co-expression of α6 and β2 cRNAs resulted in large numbers of H-epibatidine binding sites in the form of large aggregates but not in functional pentameric AChRs. Blocking Assay:Article Title: Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses Article Snippet: Many nicotinic acetylcholine receptor (AChR) subunits are known to be co-expressed with the α6 subunit in neurons.. Because α6β4 AChRs assemble inefficiently and α6β2 AChRs not at all, more complex mixtures of human subunit cDNAs were tested for their abilities to form functional AChRs when expressed in Xenopus oocytes. α6β4β3 AChRs produced the largest and most consistent responses. α6α3β2 AChRs exhibited reduced potency for ACh and increased potency and efficacy for nicotine compared to α3β2 AChRs, but similar resistance to functional inactivation after prolonged exposure to nicotine. α6α4β2 AChRs differed little in potency or efficacy for ACh or nicotine compared to α4β2 AChRs, and had similarly high sensitivity to inactivation by prolonged exposure to nicotine.. Co-expression of α6 and β2 cRNAs resulted in large numbers of H-epibatidine binding sites in the form of large aggregates but not in functional pentameric AChRs. |